Sign In
Buy ADVM
$4.36
+0 (+0%)
At Close: Mar 06, 2026
Adverum Biotechnologies Cuts Workforce, Prioritizes ADVM-022
08:07am, Thursday, 07'th Jul 2022
Adverum Biotechnologies Inc (NASDAQ: ADVM) announced a restructuring plan, including reductions in headcount and expenses, to prioritize its clinical development of ADVM-022, a single intravitreal i
Adverum Biotechnologies Completes IND Amendment and Prepares to Initiate the Phase 2 LUNA Trial of ADVM-022 in Wet AMD
08:05pm, Wednesday, 06'th Jul 2022 GlobeNewswire Inc.
- Cash runway extended into 2025 due to corporate restructuring to prioritize the clinical development of ADVM-022 and provide additional resources beyond anticipated one-year topline results of the P
Adverum Biotechnologies Granted Priority Medicines (PRIME) Designation by European Medicines Agency for ADVM-022 in Wet AMD
12:00pm, Friday, 24'th Jun 2022 GlobeNewswire Inc.
REDWOOD CITY, Calif., June 24, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases,
Adverum Biotechnologies Announces New Data at the Macula Society’s 2022 Annual Meeting
08:05pm, Thursday, 02'nd Jun 2022 GlobeNewswire Inc.
- OPTIC study of intravitreal gene therapy with ADVM-022 (AAV.7m8-aflibercept) for wet AMD shows therapeutic levels of aflibercept out to three years- New evaluation of the impact of baseline levels o
Adverum Biotechnologies Presents Research Pipeline Data Supporting Utility of its Proprietary Platform and AAV.7m8 Capsid in Ocular Gene Therapy
12:00pm, Thursday, 19'th May 2022 GlobeNewswire Inc.
REDWOOD CITY, Calif., May 19, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases,
Adverum Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
08:05pm, Monday, 09'th May 2022 GlobeNewswire Inc.
REDWOOD CITY, Calif., May 09, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases,
Adverum Biotechnologies Presents Additional Efficacy and Safety Data from the OPTIC Trial of ADVM-022 in Wet AMD at the ARVO 2022 Annual Meeting
06:15pm, Sunday, 01'st May 2022 GlobeNewswire Inc.
- Poster highlights analysis of baseline neutralizing antibodies to AAV.7m8 and impact on ADVM-022 efficacy and safety in OPTIC - - Reductions in mean annualized anti-VEGF injections ranged from 81% i
3 Stocks Under $3 Insiders Are Aggressively Buying
11:59am, Monday, 25'th Apr 2022 Benzinga
US crude oil futures traded lower on Monday. Investors, meanwhile, focused on some notable insider trades.
When insiders purchase or sell shares, it indicates their confidence or concern around the co
Adverum Biotechnologies Announces Upcoming Data Presentations at ARVO 2022
10:00pm, Tuesday, 19'th Apr 2022 GlobeNewswire Inc.
Szilárd Kiss, M.D. to present new post-hoc analyses from the Phase 1 OPTIC Trial of ADVM-022 (AAV.7m8-aflibercept) in wet AMD Szilárd Kiss, M.D. to present new post-hoc analyses from the Phase 1 OPT
Adverum (ADVM) Up on FDA Feedback for Gene Therapy Study
06:50pm, Thursday, 07'th Apr 2022 Zacks Investment Research
Adverum (ADVM) to submit IND amendment to the FDA by mid-2022 for starting a mid-stage study on its gene therapy candidate ADVM-022 for treating wet AMD eye disorder.
Adverum (ADVM) Up on FDA Feedback for Gene Therapy Study
04:34pm, Thursday, 07'th Apr 2022
Adverum (ADVM) to submit IND amendment to the FDA by mid-2022 for starting a mid-stage study on its gene therapy candidate ADVM-022 for treating wet AMD eye disorder.
The Daily Biotech Pulse: Pfizer Goes Shopping, AstraZeneca Inks Bispecific Antibody Deal, Aptinyx Faces Clinical Study Setback, Erytech Jumps On Data And More
12:24pm, Thursday, 07'th Apr 2022 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
AstraZeneca In-Licenses Preclinical Bispecific Antibody Candidate From Harbour BioMed For Up To $350M
Adverum Biotechnologies Proceeds with IND Amendment for ADVM-022 Phase 2 Trial in Wet AMD After Receiving Requested Type C Meeting Feedback from the FDA
08:05pm, Wednesday, 06'th Apr 2022 GlobeNewswire Inc.
Company anticipates completing IND amendment process by mid-2022 to enable dosing of the first patient in the planned Phase 2 trial during Third Quarter of 2022 Company anticipates completing IND amen
Adverum Biotechnologies Reports Fourth Quarter and Full Year 2021 Financial Results
08:05pm, Tuesday, 29'th Mar 2022 GlobeNewswire Inc.
REDWOOD CITY, Calif., March 29, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases
Should You Buy Adverum Biotechnologies (ADVM) Ahead of Earnings?
05:11pm, Wednesday, 02'nd Mar 2022 Zacks Investment Research
Adverum Biotechnologies (ADVM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
